Antibiotic Resistance and Phage Therapy Laboratory, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Zhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang University, Haining, Zhejiang, People's Republic of China.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0050622. doi: 10.1128/aac.00506-22. Epub 2022 Aug 11.
Bacteriophages and bacteriophage-derived peptidoglycan hydrolases (endolysins) present promising alternatives for the treatment of infections caused by multidrug resistant Gram-negative and Gram-positive pathogens. In this study, Gp105, a putative lysozyme murein hydrolase from Enterobacter phage myPSH1140 was characterized as well as using the purified protein. Gp105 contains a T4-type lysozyme-like domain (IPR001165) and belongs to Glycoside hydrolase family 24 (IPR002196). The putative endolysin indeed had strong antibacterial activity against Gram-negative pathogens, including E. cloacae, K. pneumoniae, P. aeruginosa, S. marcescens sp., and A. baumannii. Also, an peptidoglycan hydrolysis assay showed strong activity against purified peptidoglycans. This study demonstrates the potential of Gp105 to be used as an antibacterial protein to combat Gram-negative pathogens.
噬菌体和噬菌体衍生的肽聚糖水解酶（内溶素）为治疗多重耐药革兰氏阴性和革兰氏阳性病原体引起的感染提供了有前途的替代方法。在这项研究中，鉴定了肠杆菌噬菌体 myPSH1140 的假定溶菌酶 Murein 水解酶 Gp105，并使用纯化的蛋白进行了研究。Gp105 含有 T4 型溶菌酶样结构域（IPR001165），属于糖苷水解酶家族 24（IPR002196）。该内溶素确实对革兰氏阴性病原体，包括阴沟肠杆菌、肺炎克雷伯菌、铜绿假单胞菌、粘质沙雷氏菌和鲍曼不动杆菌具有很强的抗菌活性。此外，肽聚糖水解实验表明其对纯化的肽聚糖具有很强的活性。这项研究表明 Gp105 有潜力作为一种抗菌蛋白来对抗革兰氏阴性病原体。
